Evidence map›Paper›PMID 33114482›Full record

ArticleInternational journal of molecular sciences2020

Association of miR-21-5p, miR-122-5p, and miR-320a-3p with 90-Day Mortality in Cardiogenic Shock.

Mikko Hänninen, Toni Jäntti, Heli Tolppanen, Heli Segersvärd, Tuukka Tarvasmäki, Johan Lassus, Mélanie Vausort, Yvan Devaux, Alessandro Sionis, Ilkka Tikkanen and 3 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Protective effects of exerkine on cardiovascular system.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2025
    Review
  6. Article
  7. Circulating levels of miR-20b-5p are associated with survival in cardiogenic shock.Journal of molecular and cellular cardiology plus · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. TrimethylamineInternational journal of molecular sciences · 2021
    Article
  14. miR-21 in Human Cardiomyopathies.Frontiers in cardiovascular medicine · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 3 countries.

Mikko HänninenUnit of Cardiovascular Research, Minerva Foundation Institute for Medical Research, 00029 Helsinki, Finland.ORCID 0000-0002-1166-0229
Toni JänttiDepartment of Cardiology, University of Helsinki and Heart and Lung Center, Helsinki University Hospital, 00029 Helsinki, Finland.
Heli TolppanenDepartment of Cardiology, University of Helsinki and Heart and Lung Center, Helsinki University Hospital, 00029 Helsinki, Finland.
Heli SegersvärdUnit of Cardiovascular Research, Minerva Foundation Institute for Medical Research, 00029 Helsinki, Finland.
Tuukka TarvasmäkiDepartment of Cardiology, University of Helsinki and Heart and Lung Center, Helsinki University Hospital, 00029 Helsinki, Finland.ORCID 0000-0003-3406-243X
Johan LassusDepartment of Cardiology, University of Helsinki and Heart and Lung Center, Helsinki University Hospital, 00029 Helsinki, Finland.
Mélanie VausortCardiovascular Research Unit, Department of Population Health, Luxembourg Institute of Health, L-1445 Strassen, Luxembourg.ORCID 0000-0002-5261-7729
Yvan DevauxCardiovascular Research Unit, Department of Population Health, Luxembourg Institute of Health, L-1445 Strassen, Luxembourg.ORCID 0000-0002-5321-8543
Alessandro SionisIntensive Cardiac Care Unit, Cardiology Department, Biomedical Research Institute IIB-SantPau, Hospital de la Santa Creu i Sant Pau, Universidad Autónoma de Barcelona, 08041 Barcelona, Spain.
Ilkka TikkanenUnit of Cardiovascular Research, Minerva Foundation Institute for Medical Research, 00029 Helsinki, Finland.
Veli-Pekka HarjolaDivision of Emergency Medicine, University of Helsinki and Department of Emergency Services and Medicine, Helsinki University Hospital, 00029 Helsinki, Finland.
Päivi LakkistoUnit of Cardiovascular Research, Minerva Foundation Institute for Medical Research, 00029 Helsinki, Finland.ORCID 0000-0001-9935-6573
For The CardShock Study Group
University of Helsinki · FILuxembourg Institute of Health · LUMinerva Foundation · FIUniversitat Autònoma de Barcelona · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiogenic shock (CS) is a life-threatening emergency. New biomarkers are needed in order to detect patients at greater risk of adverse outcome. Our aim was to assess the characteristics of miR-21-5p, miR-122-5p, and miR-320a-3p in CS and evaluate the value of their expression levels in risk prediction. Circulating levels of miR-21-5p, miR-122-5p, and miR-320a-3p were measured from serial plasma samples of 179 patients during the first 5-10 days after detection of CS, derived from the CardShock study. Acute coronary syndrome was the most common cause (80%) of CS. Baseline (0 h) levels of miR-21-5p, miR-122-5p, and miR-320a-3p were all significantly elevated in nonsurvivors compared to survivors (

Indexed as

Acute Coronary SyndromeAgedBiomarkersFemaleGenetic Association StudiesHumansMaleMicroRNAsMiddle AgedMultivariate AnalysisShock, CardiogenicSurvival AnalysisUp-RegulationBiomarkersMicroRNAsMIRN122 microRNA, humanMIRN21 microRNA, humanMIRN320 microRNA, humancardiogenic shockmicroRNAmortalityprognosis

Identifiers

PMID33114482
PMCPMC7662780
OpenAlexW3094158746

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.